PTEN-deficient cancers depend on PIK3CB

Susan Wee, Dmitri Wiederschain, Sauveur Michel Maira, Alice Loo, Christine Miller, Rosalie DeBeaumont, Frank Stegmeier, Yung Mae Yao, Christoph Lengauer

Research output: Contribution to journalArticle

Abstract

Deregulation of the PI3K signaling pathway is observed in many human cancers and occurs most frequently through loss of PTEN phosphatase tumor suppressor function or through somatic activating mutations in the Class IA PI3K, PIK3CA. Tumors harboring activated p110α, the protein product of PIK3CA, require p110α activity for growth and survival and hence are expected to be responsive to inhibitors of its lipid kinase activity. Whether PTEN-deficient cancers similarly depend on p110α activity to sustain activation of the PI3K pathway has been unclear. In this study, we used a single-vector lentiviral inducible shRNA system to selectively inactivate the three Class IA PI3Ks, PIK3CA, PIK3CB, and PIK3CD, to determine which PI3K isoforms are responsible for driving the abnormal proliferation of PTEN-deficient cancers. Down-regulation of PIK3CA in colorectal cancer cells harboring mutations in PIK3CA inhibited downstream PI3K signaling and cell growth. Surprisingly, PIK3CA depletion affected neither PI3K signaling nor cell growth in 3 PTEN-deficient cancer cell lines. In contrast, down-regulation of the PIK3CB isoform, which encodes p110β, resulted in pathway inactivation and subsequent inhibition of growth in both cell-based and in vivo settings. This essential function of PIK3CB in PTEN-deficient cancer cells required its lipid kinase activity. Our findings demonstrate that although p110α activation is required to sustain the proliferation of established PIK3CA-mutant tumors, PTEN-deficient tumors are dependent instead on p110β signaling. This unexpected finding demonstrates the need to tailor therapeutic approaches to the genetic basis of PI3K pathway activation to achieve optimal treatment response.

Original languageEnglish (US)
Pages (from-to)13057-13062
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume105
Issue number35
DOIs
StatePublished - Sep 2 2008
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinases
Neoplasms
Growth
Protein Isoforms
Phosphotransferases
Down-Regulation
PTEN Phosphohydrolase
Lipids
Mutation
Small Interfering RNA
Colorectal Neoplasms
Cell Line
Survival
Proteins

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Wee, S., Wiederschain, D., Maira, S. M., Loo, A., Miller, C., DeBeaumont, R., ... Lengauer, C. (2008). PTEN-deficient cancers depend on PIK3CB. Proceedings of the National Academy of Sciences of the United States of America, 105(35), 13057-13062. https://doi.org/10.1073/pnas.0802655105

PTEN-deficient cancers depend on PIK3CB. / Wee, Susan; Wiederschain, Dmitri; Maira, Sauveur Michel; Loo, Alice; Miller, Christine; DeBeaumont, Rosalie; Stegmeier, Frank; Yao, Yung Mae; Lengauer, Christoph.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 35, 02.09.2008, p. 13057-13062.

Research output: Contribution to journalArticle

Wee, S, Wiederschain, D, Maira, SM, Loo, A, Miller, C, DeBeaumont, R, Stegmeier, F, Yao, YM & Lengauer, C 2008, 'PTEN-deficient cancers depend on PIK3CB', Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 35, pp. 13057-13062. https://doi.org/10.1073/pnas.0802655105
Wee S, Wiederschain D, Maira SM, Loo A, Miller C, DeBeaumont R et al. PTEN-deficient cancers depend on PIK3CB. Proceedings of the National Academy of Sciences of the United States of America. 2008 Sep 2;105(35):13057-13062. https://doi.org/10.1073/pnas.0802655105
Wee, Susan ; Wiederschain, Dmitri ; Maira, Sauveur Michel ; Loo, Alice ; Miller, Christine ; DeBeaumont, Rosalie ; Stegmeier, Frank ; Yao, Yung Mae ; Lengauer, Christoph. / PTEN-deficient cancers depend on PIK3CB. In: Proceedings of the National Academy of Sciences of the United States of America. 2008 ; Vol. 105, No. 35. pp. 13057-13062.
@article{6fdd9b2aed7d46b081a142c9aba06ea1,
title = "PTEN-deficient cancers depend on PIK3CB",
abstract = "Deregulation of the PI3K signaling pathway is observed in many human cancers and occurs most frequently through loss of PTEN phosphatase tumor suppressor function or through somatic activating mutations in the Class IA PI3K, PIK3CA. Tumors harboring activated p110α, the protein product of PIK3CA, require p110α activity for growth and survival and hence are expected to be responsive to inhibitors of its lipid kinase activity. Whether PTEN-deficient cancers similarly depend on p110α activity to sustain activation of the PI3K pathway has been unclear. In this study, we used a single-vector lentiviral inducible shRNA system to selectively inactivate the three Class IA PI3Ks, PIK3CA, PIK3CB, and PIK3CD, to determine which PI3K isoforms are responsible for driving the abnormal proliferation of PTEN-deficient cancers. Down-regulation of PIK3CA in colorectal cancer cells harboring mutations in PIK3CA inhibited downstream PI3K signaling and cell growth. Surprisingly, PIK3CA depletion affected neither PI3K signaling nor cell growth in 3 PTEN-deficient cancer cell lines. In contrast, down-regulation of the PIK3CB isoform, which encodes p110β, resulted in pathway inactivation and subsequent inhibition of growth in both cell-based and in vivo settings. This essential function of PIK3CB in PTEN-deficient cancer cells required its lipid kinase activity. Our findings demonstrate that although p110α activation is required to sustain the proliferation of established PIK3CA-mutant tumors, PTEN-deficient tumors are dependent instead on p110β signaling. This unexpected finding demonstrates the need to tailor therapeutic approaches to the genetic basis of PI3K pathway activation to achieve optimal treatment response.",
author = "Susan Wee and Dmitri Wiederschain and Maira, {Sauveur Michel} and Alice Loo and Christine Miller and Rosalie DeBeaumont and Frank Stegmeier and Yao, {Yung Mae} and Christoph Lengauer",
year = "2008",
month = "9",
day = "2",
doi = "10.1073/pnas.0802655105",
language = "English (US)",
volume = "105",
pages = "13057--13062",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "35",

}

TY - JOUR

T1 - PTEN-deficient cancers depend on PIK3CB

AU - Wee, Susan

AU - Wiederschain, Dmitri

AU - Maira, Sauveur Michel

AU - Loo, Alice

AU - Miller, Christine

AU - DeBeaumont, Rosalie

AU - Stegmeier, Frank

AU - Yao, Yung Mae

AU - Lengauer, Christoph

PY - 2008/9/2

Y1 - 2008/9/2

N2 - Deregulation of the PI3K signaling pathway is observed in many human cancers and occurs most frequently through loss of PTEN phosphatase tumor suppressor function or through somatic activating mutations in the Class IA PI3K, PIK3CA. Tumors harboring activated p110α, the protein product of PIK3CA, require p110α activity for growth and survival and hence are expected to be responsive to inhibitors of its lipid kinase activity. Whether PTEN-deficient cancers similarly depend on p110α activity to sustain activation of the PI3K pathway has been unclear. In this study, we used a single-vector lentiviral inducible shRNA system to selectively inactivate the three Class IA PI3Ks, PIK3CA, PIK3CB, and PIK3CD, to determine which PI3K isoforms are responsible for driving the abnormal proliferation of PTEN-deficient cancers. Down-regulation of PIK3CA in colorectal cancer cells harboring mutations in PIK3CA inhibited downstream PI3K signaling and cell growth. Surprisingly, PIK3CA depletion affected neither PI3K signaling nor cell growth in 3 PTEN-deficient cancer cell lines. In contrast, down-regulation of the PIK3CB isoform, which encodes p110β, resulted in pathway inactivation and subsequent inhibition of growth in both cell-based and in vivo settings. This essential function of PIK3CB in PTEN-deficient cancer cells required its lipid kinase activity. Our findings demonstrate that although p110α activation is required to sustain the proliferation of established PIK3CA-mutant tumors, PTEN-deficient tumors are dependent instead on p110β signaling. This unexpected finding demonstrates the need to tailor therapeutic approaches to the genetic basis of PI3K pathway activation to achieve optimal treatment response.

AB - Deregulation of the PI3K signaling pathway is observed in many human cancers and occurs most frequently through loss of PTEN phosphatase tumor suppressor function or through somatic activating mutations in the Class IA PI3K, PIK3CA. Tumors harboring activated p110α, the protein product of PIK3CA, require p110α activity for growth and survival and hence are expected to be responsive to inhibitors of its lipid kinase activity. Whether PTEN-deficient cancers similarly depend on p110α activity to sustain activation of the PI3K pathway has been unclear. In this study, we used a single-vector lentiviral inducible shRNA system to selectively inactivate the three Class IA PI3Ks, PIK3CA, PIK3CB, and PIK3CD, to determine which PI3K isoforms are responsible for driving the abnormal proliferation of PTEN-deficient cancers. Down-regulation of PIK3CA in colorectal cancer cells harboring mutations in PIK3CA inhibited downstream PI3K signaling and cell growth. Surprisingly, PIK3CA depletion affected neither PI3K signaling nor cell growth in 3 PTEN-deficient cancer cell lines. In contrast, down-regulation of the PIK3CB isoform, which encodes p110β, resulted in pathway inactivation and subsequent inhibition of growth in both cell-based and in vivo settings. This essential function of PIK3CB in PTEN-deficient cancer cells required its lipid kinase activity. Our findings demonstrate that although p110α activation is required to sustain the proliferation of established PIK3CA-mutant tumors, PTEN-deficient tumors are dependent instead on p110β signaling. This unexpected finding demonstrates the need to tailor therapeutic approaches to the genetic basis of PI3K pathway activation to achieve optimal treatment response.

UR - http://www.scopus.com/inward/record.url?scp=51349148948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349148948&partnerID=8YFLogxK

U2 - 10.1073/pnas.0802655105

DO - 10.1073/pnas.0802655105

M3 - Article

C2 - 18755892

AN - SCOPUS:51349148948

VL - 105

SP - 13057

EP - 13062

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 35

ER -